Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2021-04-29 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1912 characters) and contains the header 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security, which is a specific operational update related to trading mechanisms, not a comprehensive financial report or a standard corporate filing like 10-K or ER. Since it is a general regulatory announcement distributed via the RNS system and does not fit into the more specific categories (like DIV, DIRS, ER, etc.), the most appropriate classification is the general regulatory filing fallback category.
2021-04-29 English
Final Results
Earnings Release Classification · 1% confidence The document is titled 'FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020'. It contains detailed financial highlights (loss for the period, cash balance, R&D expenses) comparing 2020 results to 2019, and extensive discussion of clinical trial progress (Lupuzor™ Phase III plans) and pipeline updates. This structure is characteristic of a company's primary annual financial disclosure. Although it mentions the 'Audited Annual Report and Accounts' will be published later, the content provided here is the comprehensive summary of the full year's performance, which aligns best with the content of an Annual Report (10-K) or a very detailed Earnings Release/Interim Report. Given the comprehensive nature covering the full fiscal year (12 months ended 31 Dec 2020) and the inclusion of Chairman's Report sections, it functions as the primary annual financial disclosure. Since the text explicitly states the 'Annual Report... will today be published' and this document contains the core results and narrative, it is classified as the primary annual financial disclosure, which maps to the 10-K category for comprehensive annual reporting, even if it is presented via an RNS wrapper. The length (58k chars) also supports it being a full report rather than just a brief announcement (RPA/RNS). FY 2020
2021-04-29 English
FINAL RESULTS ANNOUNCEMENT
Earnings Release Classification · 1% confidence The document explicitly states it is the "FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020". It contains detailed financial highlights (cash balance, loss for the period, EPS) and extensive operational updates covering drug development programs (Lupuzor, BioAMB) and corporate structure changes. This content structure—a summary of annual financial performance combined with operational review—is characteristic of an Earnings Release (ER) or a section of an Annual Report. However, the text also contains a specific section titled "Audited Annual Report and Accounts" which states: "The Annual Report for the year ended 31 December 2020, will today be published on the Company's website." This strongly suggests the current document is the preliminary announcement of the annual results, not the full, comprehensive 10-K filing itself. Since it provides the key financial highlights and management commentary for the full year, it fits the definition of an Earnings Release (ER). It is not a short announcement linking to a report (RPA/RNS) because it contains substantial financial data and narrative. It is more detailed than a typical ER but less formal/structured than a full 10-K. Given the focus on 'Final Results Announcement' and key financial metrics for the full year, ER is the most appropriate classification among the choices provided, distinguishing it from the comprehensive 10-K. FY 2020
2021-04-29 English
Immupharma 2020 Final accounts 28.04.21 - signed.pdf
Audit Report / Information Classification · 1% confidence The document is titled "REPORT AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020" and contains a detailed Table of Contents listing sections like 'Chairman's Report', 'Financial Review', 'Strategic Report', 'Corporate Governance Report', 'Directors' Report', and extensive 'Consolidated Income Statement', 'Consolidated Statement of Financial Position', and 'Notes to the Consolidated Financial Statements'. This structure, covering a full fiscal year and including audited financial statements and comprehensive management/governance reports, is characteristic of an Annual Report, which corresponds to the SEC's Form 10-K filing in the US context, or a similar comprehensive annual filing globally. Given the options, '10-K' is the closest fit for a full annual report document. FY 2020
2021-04-29 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1929 chars) and contains the header 'RNS Number : 7924V'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or DLST), the most appropriate classification is the general regulatory filing fallback.
2021-04-16 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 7910V' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority...'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security, which is a type of market operational update or regulatory notification. Given the explicit reference to RNS and the nature of the announcement (not a full financial report, management change, or dividend notice), it fits best under the general Regulatory Filings category, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes. The document length is short (1912 chars), but it is the primary announcement, not an announcement *of* another report.
2021-04-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.